Navigation Links
Exelixis Receives $150 Million Funding Commitment From Deerfield Management
Date:6/5/2008

ion draw at an exercise price equal to 20% above the average of the daily volume weighted average stock price for each of the 15 trading days following the day on which Exelixis notifies Deerfield that it is drawing the funds. All warrants can be settled in net shares at Deerfield's option.

"Our deal with Deerfield provides a high level of flexibility and uniquely addresses the challenges that pre-commercial biotech companies face in a challenging capital markets environment," said Frank Karbe, chief financial officer of Exelixis. "Most notably, it provides guaranteed access to capital and a high degree of control as to when and to what degree we draw and repay funds, thereby substantially increasing our ability to manage our cost of capital and minimize dilution."

Conference Call and Webcast

Exelixis management will discuss the Deerfield arrangement during a conference call beginning at 5:00 a.m. PT/8:00 a.m. ET Thursday, June 5. To listen to a webcast of the discussion, visit the Event Calendar page under Investors at http://www.exelixis.com. An archive of the webcast will be available until 7:00 a.m. PT/10:00 a.m. ET on July 5, 2008. Access numbers for this replay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is 33494166.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmit
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... http://www.draperuniversity.com , is proud to announce that for ... 17 different countries will converge on the Draper ... for an intensive, experiential program focused on entrepreneurship, ... highly selective school, currently running its sixth cohort, ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... reporting of molecular diagnostic test results. It also ... necessary for the validation and reporting of high ... Molecular diagnostics is a rapidly growing area of ... disease, genetic predisposition, cancer, and companion diagnostics in ...
(Date:7/23/2014)... in saving China,s endangered national treasure, the giant panda. ... reserves that have been established and three large breeding ... in the wild. , Breeding programs in conservation ... improving genetic diversity, avoid inbreeding and ultimately, introduce pandas ... programs doing so far? , In a new study ...
(Date:7/23/2014)... July 23, 2014  AuraSense Therapeutics, the pioneer ... gene regulatory and immunotherapeutic agents, announced today ... AuraSense Therapeutics, executive leadership team as chief ... Prior to joining AuraSense Therapeutics, Mr. Snyder ... Officer of Cellular Dynamics International Inc., where ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2
... TAIAN CITY, China, July 16 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, ... "Company"),one of the leading plasma-based pharmaceutical companies in the ... hosted a forum of,industry experts on July 10 - ... discuss future development strategies for the Company. , ...
... , , , ... announced today that it had closed its series A financing round. The infusion ... of technology that converts a wide variety of cellulosic materials (such as algae, ... , As part of the agreement, the lead investor ...
... , HALIFAX, July 15 /PRNewswire/ - Scientists in Atlantic Canada ... skin aging. Researchers were investigating the genetic cause of a ... causes skin on the hands, feet and face to be ... delays including effects on the brain. In the process, researchers ...
Cached Biology Technology:China Biologic Products Hosts its First Forum for Strategy and Development 2China Biologic Products Hosts its First Forum for Strategy and Development 3Canadian researchers discover gene related to the appearance of aging 2
(Date:7/23/2014)... by satellite over a 15-year period off the U.S. ... feed in specific locations each year, according to a ... PLOS ONE by Ladd Irvine from Oregon ... to mitigate human threats to the whale population. , ... recover since the establishment of protections in the mid-1960s. ...
(Date:7/23/2014)... experiments using tissue samples cultured from cystic fibrosis patients, ... UNC Marsico Lung Institute have shown that a new ... another CF drug. , The finding, published today in ... a mutant CFTR protein becomes unstable and loses its ... the two drugs. The research offers several insights into ...
(Date:7/23/2014)... , , , , , , , , ... , , , , , ... researchers are proposing that changing how medical care is delivered could help prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be ... , , , , , ... , , , , , ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... gets his new laser laboratory operational later this year, ... to pluck molecular bonds like a stringed musical instrument. ... of Chemistry, arrived at the University of Chicago in ... aid of ultrafast vibrational spectroscopy methods that he has ...
... maxillary sinuses. Those bulbous pouches on either side of the ... sinus infections than anything else. They were thought to be ... present value. Yet researchers led by the University of ... role in the shape and function of the human nose, ...
... March 12, 2013  Spiral Genetics, a cloud-based big data ... A financing, led by venture capital firm DFJ.  The ... create revolutionary tools that empower the bioinformatics community to ... company intends to use the funds to expand its ...
Cached Biology News:Watery research theme to flow through new Tokmakoff lab 2Watery research theme to flow through new Tokmakoff lab 3The nose's unheralded neighbor 2The nose's unheralded neighbor 3Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia 2Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia 3
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Biology Products: